Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cysti... ( Phase 2b Trial Expected to Beg...)

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis

Date:3/4/2008

Phase 2b Trial Expected to Begin in the Second Quarter of 2008

SAN DIEGO, March 4 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Mpex orphan drug designation for levofloxacin solution for inhalation for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis. Levofloxacin is the active pharmaceutical ingredient in MP-376, the company's proprietary levofloxacin solution for inhalation.

Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa. Chronic pulmonary infections are difficult to eradicate and are implicated as the major cause of deterioration of pulmonary function and associated morbidity and mortality in CF patients. Chronic infection is associated with pulmonary exacerbations due to bacterial overgrowth, and a decrease in lung function over time from inflammation triggered by bacteria and their toxins.

"Obtaining orphan drug designation for MP-376 in cystic fibrosis is an important milestone for the program," stated Daniel Burgess, President and Chief Executive Officer of Mpex Pharmaceuticals, Inc. "This helps reinforce our belief that MP-376 has the potential to provide a valuable new treatment option in the management of cystic fibrosis. We look forward to working with CF patients, treatment providers and the FDA to rapidly advance this product candidate through to commercialization."

Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 Americans annually. Orphan drug designation will entitle Mpex to a seven-year period of exclusive marketing rights for MP-376 for the orphan indication following the date of the drug
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Animal Imaging
2. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
3. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
5. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Raptor Pharmaceuticals Acquires Orphan Clinical Program
8. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
9. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
10. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
11. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe

Post Your Comments:

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cysti...( Phase 2b Trial Expected to Beg...)